Pasithea Therapeutics Corp Cash Flow Conversion Efficiency
Pasithea Therapeutics Corp cash flow conversion efficiency. Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has a cash flow conversion efficiency ratio of -0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pasithea Therapeutics Corp (2020–2024)
Cash flow conversion efficiency of Pasithea Therapeutics Corp from 2020 to 2024. This chart illustrates how Pasithea Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pasithea Therapeutics Corp stock price for real-time trading data and today's change.
Pasithea Therapeutics Corp Cash Flow Conversion Ratio Explained
Pasithea Therapeutics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pasithea Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pasithea Therapeutics Corp ranked by their cash flow conversion efficiency. Also see how much is Pasithea Therapeutics Corp worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Era Helium Inc Common Stock
NASDAQ:NEHC
|
0.362x |
|
Polyrizon Ltd. Ordinary Shares
NASDAQ:PLRZ
|
-0.099x |
|
AVI Global Trust PLC
LSE:AGT
|
0.006x |
|
Ryukil C&S Ltd
KQ:191410
|
-0.033x |
|
HEC Infra Projects Limited
NSE:HECPROJECT
|
0.057x |
|
Fastator AB
ST:FASTAT
|
-0.029x |
|
Just Group plc
LSE:JUST
|
0.765x |
|
MedX Health Corp
V:MDX
|
0.069x |
Annual Cash Flow Conversion Efficiency for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual cash flow conversion efficiency of Pasithea Therapeutics Corp from 2020 to 2024. Review KTTA financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.78 Million | $-13.92 Million | -0.942x | -64.15% |
| 2023-12-31 | $23.40 Million | $-13.43 Million | -0.574x | -78.10% |
| 2022-12-31 | $42.50 Million | $-13.69 Million | -0.322x | -421.90% |
| 2021-12-31 | $51.42 Million | $-3.17 Million | -0.062x | +61.49% |
| 2020-12-31 | $241.35K | $-38.69K | -0.160x | -- |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more